Monitor Q32 Bio for the initiation of the registration-directed trial for bempikibart in alopecia areata, expected in the first half of 2027. The next key catalyst will be data readouts from the SIGNAL-AA program. The executive hires add credibility but do not change the near-term risk/reward profile.
Price Chart
Executive Summary
Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer, both with strong late-stage development and regulatory backgrounds. The hires signal the company's transition toward a registration-directed program for bempikibart in alopecia areata, with a registrational trial expected in the first half of 2027. This is a routine executive appointment with no financial data or material business changes disclosed, making it a neutral event for traders.
Key Facts
- Q32 Bio appointed Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer on September 14, 2026.
- Dr. Trevejo previously served as CMO at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of XDEMVY.
- Dr. Hershberger previously served as CDO at Adagio Therapeutics (now Invivyd), contributing to its IPO that raised approximately $356 million in gross proceeds.
- The company plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.
- No financial figures, guidance, or material business changes were disclosed in this filing.
Financial Impact
No financial impact disclosed in this filing.
Risk Factors
- Clinical trial risk for bempikibart in alopecia areata
- Capital requirements to fund registration-directed program
- Competition from existing and emerging alopecia areata therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-389836 |
| Document: d158730dex991.htm | 0001193125-26-389836 |
| Document: 0001193125-26-389836-index-headers.html | 0001193125-26-389836 |
| Document: 0001193125-26-389836-index.html | 0001193125-26-389836 |
| Document: 0001193125-26-389836.txt | 0001193125-26-389836 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 8-K | $10.91 $10.47 | ▼ −4.03% | ▼ −4.14% | $8.34 (−23.56%) |
Aug 27, 2026 5w ago | Insider Cluster | $16.15 $12.80 | ▼ −20.74% | ▼ −21.01% | $8.34 (−48.36%) |
Aug 5, 2026 8w ago | 8-K | $16.49 $15.37 | ▼ −6.79% | ▼ −7.14% | $8.34 (−49.42%) |
Jul 15, 2026 11w ago | Press Release | $15.70 $15.08 | ▲ +3.95% | ▲ +2.97% | $8.34 (+46.88%) |
Jul 14, 2026 11w ago | EFFECT | $18.46 $15.04 | ▼ −18.53% | ▼ −17.23% | $8.34 (−54.82%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.34 (−60.99%) |
Jul 13, 2026 11w ago | 8-K | $21.38 $15.05 | ▼ −29.61% | ▼ −28.82% | $8.34 (−60.99%) |
Jun 25, 2026 14w ago | S-3 | $13.17 $13.09 | ▼ −0.61% | ▼ −2.77% | $8.34 (−36.67%) |
Jun 2, 2026 17w ago | Insider Cluster | $12.64 $11.89 | ▼ −5.93% | ▼ −2.97% | $8.34 (−34.02%) |
May 5, 2026 21w ago | 8-K | $5.14 $5.81 | ▲ +13.04% | ▲ +11.05% | $8.34 (+62.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access